# Mansoor Raza Mirza

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/mansoor-raza-mirza/

## Facts

| Field | Value |
| --- | --- |
| Citations | 21,435 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 58 |
| i10-index | 151 |
| Last Known Institution | C4 Therapeutics (United States) |
| OpenAlex ID | https://openalex.org/A5079485962 |
| ORCID iD | 0000-0002-8085-1010 |
| Works | 476 |

## Researcher papers

Showing 12 of 17.

- [ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma](https://scholariq.org/papers/esgo-estro-esp-guidelines-for-the-management-of-patients-with-endometrial/)
- [Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial](https://scholariq.org/papers/bevacizumab-combined-with-chemotherapy-for-platinum-resistant-recurrent-ovarian/)
- [ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up](https://scholariq.org/papers/esmo-esgo-estro-consensus-conference-on-endometrial-cancer-diagnosis-treatment/)
- [ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease](https://scholariq.org/papers/esmo-esgo-consensus-conference-recommendations-on-ovarian-cancer-pathology-and/)
- [Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial](https://scholariq.org/papers/standard-chemotherapy-with-or-without-bevacizumab-for-women-with-newly-diagnosed/)
- [Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer](https://scholariq.org/papers/dostarlimab-for-primary-advanced-or-recurrent-endometrial-cancer/)
- [ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer](https://scholariq.org/papers/esmo-esgo-estro-consensus-conference-on-endometrial-cancer/)
- [Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/endometrial-cancer-esmo-clinical-practice-guideline-for-diagnosis-treatment-and/)
- [Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study](https://scholariq.org/papers/efficacy-and-safety-of-tisotumab-vedotin-in-previously-treated-recurrent-or/)
- [The forefront of ovarian cancer therapy: update on PARP inhibitors](https://scholariq.org/papers/the-forefront-of-ovarian-cancer-therapy-update-on-parp-inhibitors/)
- [European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer - Update 2023](https://scholariq.org/papers/european-society-of-gynaecological-oncology-guidelines-for-the-management-of-2/)
- [Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆](https://scholariq.org/papers/niraparib-maintenance-therapy-in-patients-with-platinum-sensitive-recurrent/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer, Lipids, and Metabolism](https://scholariq.org/topics/cancer-lipids-and-metabolism/)

## Researcher university

- [C4 Therapeutics (United States)](https://scholariq.org/institutions/c4-therapeutics-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.